Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

Published:2008-11-17 Issue:6 Volume:68 Page:805-811
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Annals of the Rheumatic Diseases

Author:

Fleischmann R,Vencovsky J,van Vollenhoven R F,Borenstein D,Box J,Coteur G,Goel N,Brezinschek H-P,Innes A,Strand V

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Cited by 279 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients;Frontiers in Medicine;2024-09-04

2. Certolizumab Has Favorable Efficacy on Preventing Pancreas and Target Organs Damage in Acute Pancreatitis;Pancreas;2024-08

3. Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis;Expert Opinion on Biological Therapy;2024-07-25

4. Current Prospects in Rheumatoid Arthritis: Pathophysiology, Genetics, and Treatments;Recent Advances in Anti-Infective Drug Discovery;2024-04

5. Certolizumab pegol in severe rheumatoid arthritis: Real-world evidence in an Argentine cohort: Achievement of targets (T2T) at 3 months and predictive factors.;Global Rheumatology;2024-02-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP